Genome-wide DNA methylation patterns in naive cd4+ t cells from patients with primary sjögren's syndrome

Arthritis and Rheumatology

Volumn 66, Issue 3, 2014, Pages 731-739

  Altorok, Nezam ^a   Coit, Patrick ^b   Hughes, Travis ^b   Koelsch, Kristi A ^c   Stone, Donald U ^d   Rasmussen, Astrid ^c   Radfar, Lida ^d   Scofield, R Hal ^d   Sivils, Kathy L ^c   Farris, A Darise ^c   Sawalha, Amr H ^b,e  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BISULFITE; CYTOSINE; DEATH RECEPTOR 3; GLUTATHIONE TRANSFERASE M1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; ORGANIC CATION TRANSPORTER; PROGRAMMED DEATH 1 LIGAND 1; SODIUM PROTON EXCHANGE PROTEIN 1; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR RUNX1;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; ETHNICITY; FEMALE; GENE LOCUS; GENE ONTOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; YOUNG ADULT;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 84896266991     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38264     Document Type: Article

References (42)

1. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
2. Delaleu N, Jonsson R, Koller MM. Sjögren's syndrome. Eur J Oral Sci 2005;113:101-13.
3. Hughes GR, Whaley K. Sjögren's syndrome. Br Med J 1972;4: 533-6.
4. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
5. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004;164: 1275-84.
6. Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013;25: 569-76.
7. Thabet Y, Le Dantec C, Ghedira I, Devauchelle V, Cornec D, Pers JO, et al. Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells. J Autoimmun 2013;41:175-81.
8. Jeffries MA, Sawalha AH. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumatol 2011;6:423-39.
9. Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferonregulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013;43:78-84.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
12. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
13. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003;4:235-40.
14. Bird A. Il2 transcription unleashed by active DNA demethylation. Nat Immunol 2003;4:208-9.
15. Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J 2006;25:1081-92.
16. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010;35: 225-31.
17. Rennert PD, James D, Mackay F, Browning JL, Hochman PS. Lymph node genesis is induced by signaling through the lymphotoxin β receptor. Immunity 1998;9:71-9.
18. Fava RA, Browning JL, Gatumu M, Skarstein K, Bolstad AI. LTBR-pathway in Sjögren's syndrome: CXCL13 levels and B-cellenriched ectopic lymphoid aggregates in NOD mouse lacrimal glands are dependent on LTBR. Adv Exp Med Biol 2011;691: 383-90.
19. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005;23:787-819.
20. Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, et al. Characterization of surface lymphotoxin forms: use of specific monoclonal antibodies and soluble receptors. J Immunol 1995;154:33-46.
21. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433.
22. Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade of lymphotoxin-β receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009;11:R24.
23. Shen L, Suresh L, Wu J, Xuan J, Li H, Zhang C, et al. A role for lymphotoxin in primary Sjögren's disease. J Immunol 2010;185: 6355-63.
24. Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, et al. IL-14α, the nexus for primary Sjögren's disease in mice and humans. Clin Immunol 2009;130:304-12.
25. Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, et al. Lymphotoxin-β receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. Arthritis Res Ther 2011;13: R182.
26. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
27. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-96.
28. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007;56:3588-600.
29. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44.
30. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006;103:2770-5.
31. Weissman AM, Hou D, Orloff DG, Modi WS, Seuanez H, O'Brien SJ, et al. Molecular cloning and chromosomal localization of the human T-cell receptor ζ chain: distinction from the molecular CD3 complex. Proc Natl Acad Sci U S A 1988;85:9709-13.
32. Clark MC, Pang M, Hsu DK, Liu FT, de Vos S, Gascoyne RD, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012;120: 4635-44.
33. Sun ZF, Zhang J, Xu HM, Wang GL, Dong P. Association between GSTM1 polymorphism and nasopharyngeal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev 2012;13: 5817-21.
34. Morinobu A, Kanagawa S, Koshiba M, Sugai S, Kumagai S. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjögren's syndrome in Japanese individuals. Arthritis Rheum 1999;42:2612-5.
35. Cobb BL, Fei Y, Jonsson R, Bolstad AI, Brun JG, Rischmueller M, et al. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1731-2.
36. Okuda T, Nishimura M, Nakao M, Fujita Y. RUNX1/AML1: a central player in hematopoiesis. Int J Hematol 2001;74:252-7.
37. Asou N. The role of a Runt domain transcription factor AML1/ RUNX1 in leukemogenesis and its clinical implications [published erratum appears in Crit Rev Oncol Hematol 2006;60:87]. Crit Rev Oncol Hematol 2003;45:129-50.
38. Kundu M, Compton S, Garrett-Beal L, Stacy T, Starost MF, Eckhaus M, et al. Runx1 deficiency predisposes mice to Tlymphoblastic lymphoma. Blood 2005;106:3621-4.
39. Nikolov NP, Illei GG. Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2009;21:465-70.
40. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins: introduction. Pflugers Arch 2004;447:465-8.
41. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. Rheumatology (Oxford) 1999;38:1113-20.
42. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol 2012;41:161-76.